• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
186555 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
* \1 }: A' v) K1 V# y8 x
可以,但要有针对性,
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  0 |8 g* X0 ^  }; A
4 R# L- j6 l4 K& w* E* h) m

( y6 Z; ^% p7 V' ?; hSub-category:" w/ f3 g3 g0 F" z3 l
Molecular Targets
2 V) m8 y0 R3 M! V7 Y+ O  O8 ^& y0 |/ J8 \6 G( z; a9 [. V

, {3 |& f1 c; M( T: N% lCategory:
4 d# B9 @+ J# n- j: B+ F- z* o8 BTumor Biology 4 }: C7 i& S) D7 J" d8 X$ E% u

" k& x# D3 w" c6 I
5 x- c2 s2 v, x/ m3 {" I& @Meeting:# o' B- |( A* l% E# C
2011 ASCO Annual Meeting : c1 [6 \# h4 F# a5 A, J+ d
' K! z# S& h  @- v/ g& H/ O; M! r

9 r1 ]3 {, z9 v' F+ H" r$ i5 [Session Type and Session Title:
3 C  N: j6 E: `Poster Discussion Session, Tumor Biology 7 \5 k- L" W" q8 _' V7 ?

' _" E5 o4 f+ `9 d; F" V# W: t1 _. h2 U. ]/ X* x! s
Abstract No:
$ k1 v  h3 y' B( x8 J1 [10517 , ?! f# Q9 e  M8 C# ?% ~
; s/ }3 B  @& U9 \' {" O; ^

, E$ e0 t! w3 y  }8 A# q4 v% OCitation:: j$ s8 m+ d4 q4 O: E1 e
J Clin Oncol 29: 2011 (suppl; abstr 10517)
" X1 v2 b& O5 N! K( I/ N" C" a! D3 q* L8 A8 S1 g8 N; F

% y1 u1 h: n5 f$ U% o8 B& BAuthor(s):
" X1 m* T7 e) {/ wJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China . c& c6 `8 U6 j5 d/ |: L
/ |5 }- j' `2 S9 ^) p: c- @
7 j, w8 p1 l  ~5 D7 Q+ ~+ H
  e; T( x& A! Z  w- U& r* Y0 y
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings., _. q4 \, T. {

" E/ w& k3 H. e) p* eAbstract Disclosures
3 u. S7 D$ t' t0 B' J8 E: j1 J: B4 l% l; R' ^6 a% V# p5 v' {
Abstract:
2 H7 b1 p9 J1 g& w9 e7 d* i
  J2 \! _( c# a5 p0 Q% x) {# [0 H; Z/ V% U
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
. R9 Y3 G& {( ~' J% C/ L+ I
& h9 t! ?3 P/ Y2 L4 K
+ @' P; N3 n8 K9 R6 K) v
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 " {4 i, j" \; Y- y! a1 @2 C. i
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
% @2 a% @. V1 J, d  g& Q1 @
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 , ]% R' r& o$ d( t6 l: M
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
9 o& X8 I8 C1 P4 O! j4 FALK一个指标医院要900多 ...

' R$ d1 K) D! c* f4 a平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?1 ^0 W$ t! V2 H& v

9 R* F! w- `. I( a0 C% _现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表